3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow Transurethral Resection of Bladder: new trials by email Literature Review of Transurethral Resection of Bladder trials Research Report on Transurethral Resection of Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine - Muscle-invasive Urothelial Cancer of the Bladder | Phase 2 | Completed | NYU Langone Health | 60 | 2016-08-11 | 2026-09-30 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
Melanoma (1)
Fox Chase Cancer Center (1) · NYU Langone Health (1) · University of Kansas Medical Center (1)
United States (3)
Minas Economides, MD (1) · Muhammad Umair Mushtaq (1)
PMID 33660142, PMID 39680823, PMID 40343719
P30CA168524 (1)